Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

AACE 2021 May 26 - 29

Once-Weekly Subcutaneous Semaglutide 2.4 mg Plus Intensive Behavioral Therapy Produces Clinically Meaningful Weight Loss in Adults with Overweight/Obesity Regardless of Baseline Characteristics and Weight History

W. Timothy Garvey1; Dan Hesse2; Thomas Holst-Hansen2; Anna Koroleva2; Robert F. Kushner3; Soo Lim4; Ildiko Lingvay5; Ofri Mosenzon6; Thomas A. Wadden7; Carel W. le Roux8;
1Department of Nutrition Sciences, University of Alabama at Birmingham/Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA; 2Novo Nordisk A/S, Søborg, Denmark; 3Division of Endocrinology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 4Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea; 5Department of Internal Medicine/Endocrinology and Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA; 6Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; 7Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 8Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland;